Clinical and biological prognostic factors in follicular lymphoma patients
<h4>Introduction</h4> Follicular lymphoma (FL) is an indolent, yet heterogeneous, B-cell lymphoproliferative disorder. Although most FL patients respond well to treatment, few with specific traits have a poor prognosis; the latter are difficult to define. <h4>Patients and methods&l...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351995/?tool=EBI |
| _version_ | 1811315153586618368 |
|---|---|
| author | Ádám Jóna Anna Kenyeres Sándor Barna Árpád Illés Zsófia Simon |
| author_facet | Ádám Jóna Anna Kenyeres Sándor Barna Árpád Illés Zsófia Simon |
| author_sort | Ádám Jóna |
| collection | DOAJ |
| description | <h4>Introduction</h4> Follicular lymphoma (FL) is an indolent, yet heterogeneous, B-cell lymphoproliferative disorder. Although most FL patients respond well to treatment, few with specific traits have a poor prognosis; the latter are difficult to define. <h4>Patients and methods</h4> We retrospectively analyzed data from 143 FL patients treated at the University of Debrecen since 2009 and investigated prognostic factors that may influence the survival of FL patients. <h4>Results</h4> A maximum standardized uptake value (SUVmax) cut-off of 9.85 at the staging positron emission tomography/computed tomography (PET/CT) (p = 0.0001, hazard ratio [HR]: 0.2535, 95% confidence interval [CI]: 0.1118–0.4878) and a lymphocyte/monocyte (Ly/Mo) ratio of 3.41 (p = 0.0027, HR: 2.997, 95% CI: 1.463–6.142), drawn at diagnosis, significantly predicted FL patients’ progression-free survival (PFS). A staging SUVmax >9.85 with Ly/Mo <3.41 could delineate a high-risk group of FL patients (p<0.0001, HR: 0.0957, 95% CI: 0.03416–0.2685). Similarly, a significant difference was shown with an SUVmax cut-off of 3.15 at the interim PET/CT (p<0.0001, HR: 0.1614, 95% CI: 0.06684–0.3897). A staging SUVmax >9.85 in conjunction with interim SUVmax >3.15 predicted poor prognosis (p<0.0001, HR: 0.1037, 95% CI: 0.03811–0.2824). The PFS difference was translated into overall survival (OS) advantage (p = 0.0506, HR: 0.1187, 95% CI: 0.01401–1.005). <h4>Conclusion</h4> Biological prognostic factors, such as the Ly/Mo ratio, may improve the prognostic assessment of staging PET/CT. The survival advantage observed in PFS is translated into OS when determined using a combination of staging and interim SUVmax. We recommend investigating additional biological prognostic factors while highlighting the role of PET/CT in FL. |
| first_indexed | 2024-04-13T11:25:07Z |
| format | Article |
| id | doaj.art-4da0e648d2f347b882637e6cc051fedf |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T11:25:07Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-4da0e648d2f347b882637e6cc051fedf2022-12-22T02:48:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01178Clinical and biological prognostic factors in follicular lymphoma patientsÁdám JónaAnna KenyeresSándor BarnaÁrpád IllésZsófia Simon<h4>Introduction</h4> Follicular lymphoma (FL) is an indolent, yet heterogeneous, B-cell lymphoproliferative disorder. Although most FL patients respond well to treatment, few with specific traits have a poor prognosis; the latter are difficult to define. <h4>Patients and methods</h4> We retrospectively analyzed data from 143 FL patients treated at the University of Debrecen since 2009 and investigated prognostic factors that may influence the survival of FL patients. <h4>Results</h4> A maximum standardized uptake value (SUVmax) cut-off of 9.85 at the staging positron emission tomography/computed tomography (PET/CT) (p = 0.0001, hazard ratio [HR]: 0.2535, 95% confidence interval [CI]: 0.1118–0.4878) and a lymphocyte/monocyte (Ly/Mo) ratio of 3.41 (p = 0.0027, HR: 2.997, 95% CI: 1.463–6.142), drawn at diagnosis, significantly predicted FL patients’ progression-free survival (PFS). A staging SUVmax >9.85 with Ly/Mo <3.41 could delineate a high-risk group of FL patients (p<0.0001, HR: 0.0957, 95% CI: 0.03416–0.2685). Similarly, a significant difference was shown with an SUVmax cut-off of 3.15 at the interim PET/CT (p<0.0001, HR: 0.1614, 95% CI: 0.06684–0.3897). A staging SUVmax >9.85 in conjunction with interim SUVmax >3.15 predicted poor prognosis (p<0.0001, HR: 0.1037, 95% CI: 0.03811–0.2824). The PFS difference was translated into overall survival (OS) advantage (p = 0.0506, HR: 0.1187, 95% CI: 0.01401–1.005). <h4>Conclusion</h4> Biological prognostic factors, such as the Ly/Mo ratio, may improve the prognostic assessment of staging PET/CT. The survival advantage observed in PFS is translated into OS when determined using a combination of staging and interim SUVmax. We recommend investigating additional biological prognostic factors while highlighting the role of PET/CT in FL.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351995/?tool=EBI |
| spellingShingle | Ádám Jóna Anna Kenyeres Sándor Barna Árpád Illés Zsófia Simon Clinical and biological prognostic factors in follicular lymphoma patients PLoS ONE |
| title | Clinical and biological prognostic factors in follicular lymphoma patients |
| title_full | Clinical and biological prognostic factors in follicular lymphoma patients |
| title_fullStr | Clinical and biological prognostic factors in follicular lymphoma patients |
| title_full_unstemmed | Clinical and biological prognostic factors in follicular lymphoma patients |
| title_short | Clinical and biological prognostic factors in follicular lymphoma patients |
| title_sort | clinical and biological prognostic factors in follicular lymphoma patients |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351995/?tool=EBI |
| work_keys_str_mv | AT adamjona clinicalandbiologicalprognosticfactorsinfollicularlymphomapatients AT annakenyeres clinicalandbiologicalprognosticfactorsinfollicularlymphomapatients AT sandorbarna clinicalandbiologicalprognosticfactorsinfollicularlymphomapatients AT arpadilles clinicalandbiologicalprognosticfactorsinfollicularlymphomapatients AT zsofiasimon clinicalandbiologicalprognosticfactorsinfollicularlymphomapatients |